Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
- 1 March 2018
- journal article
- editorial
- Published by Elsevier BV in Clinical Microbiology & Infection
- Vol. 24 (3), 216-218
- https://doi.org/10.1016/j.cmi.2017.12.003
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary TuberculosisJournal of Thoracic Oncology, 2016
- Molecular and Biochemical Aspects of the PD-1 Checkpoint PathwayThe New England Journal of Medicine, 2016
- Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1Journal of Leukocyte Biology, 2016
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of MelanomaClinical Infectious Diseases, 2016
- CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal DiseasePLoS Pathogens, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphomaActa Oncologica, 2016
- PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology, 2015
- Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic optionsRetrovirology, 2015
- Clinical blockade of PD1 and LAG3 — potential mechanisms of actionNature Reviews Immunology, 2014